These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 3536545)

  • 1. Abnormal T-lymphocyte colonies (CFU-TL) following bone marrow transplantation.
    Mitsuyasu RT; Li SN; Champlin RE; Gale RP
    Exp Hematol; 1986 Dec; 14(11):1049-55. PubMed ID: 3536545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution.
    Guillaume T; Sekhavat M; Rubinstein DB; Hamdan O; Leblanc P; Symann ML
    Cancer Res; 1994 Jul; 54(14):3800-7. PubMed ID: 7913409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell phenotypic profile and colony formation during recovery from cytotoxic therapy-induced marrow aplasia.
    Ashkenazi YJ; Barth KC; Elfenbein GJ
    Cancer Res; 1985 Dec; 45(12 Pt 1):6513-8. PubMed ID: 3933827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation.
    Bosly AE; Staquet PJ; Doyen CM; Chatelain BJ; Humblet YP; Symann ML
    Exp Hematol; 1987 Nov; 15(10):1048-54. PubMed ID: 3311785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
    Mumcuoglu M; Naparstek E; Slavin S
    Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation.
    Li S; Champlin R; Fitchen JH; Gale RP
    J Clin Invest; 1985 Jan; 75(1):234-41. PubMed ID: 3880774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
    Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
    Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.
    Novitzky N; Mohamed R
    Exp Hematol; 1995 Dec; 23(14):1661-6. PubMed ID: 8542962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant.
    Selleri C; Maciejewski JP; De Rosa G; Raiola A; Risitano AM; Picardi M; Pezzullo L; Luciano L; Ricci P; Varriale G; Della Cioppa P; Del Vecchio L; Rotoli B
    Bone Marrow Transplant; 1999 May; 23(10):1029-37. PubMed ID: 10373069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation.
    Podestà M; Piaggio G; Frassoni F; Pitto A; Mordini N; Bregante S; Valeriani A; Bacigalupo A
    Bone Marrow Transplant; 1997 May; 19(10):1011-7. PubMed ID: 9169645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex.
    Raff RF; Sandmaier BM; Graham T; Loughran TP; Pettinger M; Storb R
    Exp Hematol; 1994 Aug; 22(9):893-7. PubMed ID: 8062888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment.
    Douay L; Gorin NC; Mary JY; Lemarie E; Lopez M; Najman A; Stachowiak J; Giarratana MC; Baillou C; Salmon C
    Exp Hematol; 1986 Jun; 14(5):358-65. PubMed ID: 3519263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
    Bentley SA; Brecher ME; Powell E; Serody JS; Wiley JM; Shea TC
    Bone Marrow Transplant; 1997 Mar; 19(6):557-63. PubMed ID: 9085735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.
    Zheng Z; Qianqiao Z; Qi H; Feng X; Chunkang C; Xiao L
    Exp Hematol; 2010 Aug; 38(8):677-84. PubMed ID: 20394797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
    Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
    Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of hemopoietic stromal fibroblastic colonies in patients undergoing bone marrow transplantation.
    Da WM; Ma DD; Biggs JC
    Exp Hematol; 1986 May; 14(4):266-70. PubMed ID: 3516714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.